February 13, 2020 / 12:27 PM / 9 days ago

BRIEF-Can-Fite Submits Liver Cancer Phase Iii Protocol And Registration Plan To EMA For Namodenoson

Feb 13 (Reuters) - Can Fite Biopharma Ltd:

* CAN-FITE SUBMITS LIVER CANCER PHASE III PROTOCOL AND REGISTRATION PLAN TO EMA FOR NAMODENOSON Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below